Chimeric Antigen Receptors for T-Cell Malignancies

Development of chimeric antigen receptor (CAR)-modified T cells for the treatment of T-lineage leukemia and lymphoma has encountered several unique challenges. The most widely expressed tumor antigen targets for malignant T cells are often also expressed on non-malignant T cells. Transducing T cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Scherer, Lauren D., Brenner, Malcolm K., Mamonkin, Maksim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411696/
https://www.ncbi.nlm.nih.gov/pubmed/30891427
http://dx.doi.org/10.3389/fonc.2019.00126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411696/
https://www.ncbi.nlm.nih.gov/pubmed/30891427
http://dx.doi.org/10.3389/fonc.2019.00126

Ejemplares similares